


**IN THE CLAIMS:**

1 – 16. (Previously canceled)

17. (Currently amended) A synergistic antineoplastic composition [product] containing an alkylating anthracycline of formula Ia or Ib:



and an antimetabolite compound as a combined preparation that has a synergistic antineoplastic effect for use in treatment of tumors in mammals.

18. (Currently amended) The [product] composition according to claim 17, further containing a pharmaceutically acceptable carrier or excipient.

19. (Currently canceled) The product according to claim 17 or claim 18, wherein the mammal is a human.

20. (Currently amended) The [product] composition according to claim 17 or claim 18 wherein the alkylating anthracycline is a 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methanesulfonyl daunorubicin.

21. (Currently amended) [ A product] The composition according to claim 17 or claim 18 wherein the antimetabolite compound is a cytidine analog.

22. (Currently amended) [A product] The composition according to claim 17 or claim 18 wherein the antimetabolite compound is a 5-fluoropyrimidine.
23. (Currently amended) [A product] The composition according to claim 21 wherein the cytidine analog is gemcitabine.
24. (Currently amended) [A product] The composition according to claim 22 wherein the 5-fluoropyrimidine is 5-fluorouracil.
25. (Previously amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and, as an active ingredient, an alkylating anthracycline of formula Ia or Ib as defined in claim 17 and an antimetabolite compound that has a synergistic antineoplastic effect in mammals.
26. (Currently canceled) A pharmaceutical composition according to claim 25 wherein the mammal is a human.
27. (Currently amended) [A] The pharmaceutical composition according to claim 25 or claim 26 wherein the antimetabolite compound is 5-fluorouracil or gemcitabine.
28. (Previously presented) A method for treating tumors in a mammal in need thereof, comprising administering the alkylating anthracycline of formula Ia or Ib and an antimetabolite compound as claimed in claim 17 or claim 18 to said mammal in a synergistic antineoplastic effective amount.
29. (Previously presented) The method according to claim 28 wherein the mammal is a human.
30. (Currently twice amended) The method according to claim 28 [or claim 29] wherein the antimetabolite compound is 5-fluorouracil or gemcitabine.
31. (Previously canceled)
32. (Currently amended) [A method for treatment of metastasis in a mammal in need thereof, comprising administering the alkylating anthracycline of formula Ia or Ib and an

antimetabolite compound as claimed in claim 17 or claim 18 to said mammal in a synergistic antineoplastic effective amount] The method according to claim 29 wherein the antimetabolite compound is 5-fluorouracil or gemcitabine.

33. (Currently canceled) The method according to claim 32 wherein the mammal is a human.

34. (Currently canceled) The method according to claim 32 or claim 33 wherein the antimetabolite compound is 5-fluorouracil or gemcitabine.

35. (Previously canceled)

36. (Previously presented) A method for treating a tumor by the inhibition of angiogenesis in a mammal in need thereof, comprising administering the alkylating anthracycline of formula Ia or Ib and an antimetabolite compound as claimed in claim 17 or claim 18 to said mammal in a synergistic antineoplastic effective amount.

37. (Previously presented) The method according to claim 36 wherein the mammal is a human.

38. (Currently twice amended) The method according to claim 36 [or claim 37] wherein the antimetabolite compound is 5-fluorouracil or gemcitabine.

39. (Canceled)

40. (New) The method according to claim 37 wherein the antimetabolite compound is 5-fluorouracil or gemcitabine.

41. (New) A method for treatment of metastasis in a mammal in need thereof, comprising administering the alkylating anthracycline of formula Ia or Ib and an antimetabolite compound as claimed in claim 17 or claim 18 to said mammal in a synergistic antineoplastic effective amount.

42. (New) The method according to claim 41 wherein the mammal is a human.

43. (New) The method according to claim 41 wherein the antimetabolite compound is 5-fluorouracil or gemcitabine.
44. (New) The method according to claim 42 wherein the antimetabolite compound is 5-fluorouracil or gemcitabine.